View in EDS HTML Full Text PDF Full Text

Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.

Saved in:
Bibliographic Details
Title: Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.
Authors: Li Z; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Qu H; Department of Pharmacy, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China., Wang S; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Liu Z; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China., Wu Z; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Hu S; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Yang R; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Yan Q; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Wu D; School of Medicine, Shanghai University, Shanghai, China., Lou Y; Department of Pharmacy, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China., Fan G; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Source: Frontiers in immunology [Front Immunol] 2026 Jun 18; Vol. 17, pp. 1759135. Date of Electronic Publication: 2026 Jun 18 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42396449
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+Z%22">Li Z</searchLink>; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Qu+H%22">Qu H</searchLink>; Department of Pharmacy, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+S%22">Wang S</searchLink>; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+Z%22">Liu Z</searchLink>; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wu+Z%22">Wu Z</searchLink>; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Hu+S%22">Hu S</searchLink>; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yang+R%22">Yang R</searchLink>; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yan+Q%22">Yan Q</searchLink>; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wu+D%22">Wu D</searchLink>; School of Medicine, Shanghai University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Lou+Y%22">Lou Y</searchLink>; Department of Pharmacy, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Fan+G%22">Fan G</searchLink>; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Jun 18; Vol. 17, pp. 1759135. <i>Date of Electronic Publication: </i>2026 Jun 18 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42396449
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2026.1759135
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1759135
    Titles:
      – TitleFull: Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li Z
      – PersonEntity:
          Name:
            NameFull: Qu H
      – PersonEntity:
          Name:
            NameFull: Wang S
      – PersonEntity:
          Name:
            NameFull: Liu Z
      – PersonEntity:
          Name:
            NameFull: Wu Z
      – PersonEntity:
          Name:
            NameFull: Hu S
      – PersonEntity:
          Name:
            NameFull: Yang R
      – PersonEntity:
          Name:
            NameFull: Yan Q
      – PersonEntity:
          Name:
            NameFull: Wu D
      – PersonEntity:
          Name:
            NameFull: Lou Y
      – PersonEntity:
          Name:
            NameFull: Fan G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 06
              Text: 2026 Jun 18
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1